title: Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT.
abstract: We report on a 61-year-old man with elevated serum prostate-specific antigen level of 10.5 ng/mL who had undergone prior negative standard transrectal ultrasound biopsy at another institution. He was referred to our medical center for evaluation and underwent a clinical 3-T multiparametric MRI and a research protocol PET/CT with the cellular proliferation radiotracer (18)F-FMAU (2'-deoxy-2'-[(18)F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil). The PET/CT and multiparametric MRI were fused with transrectal ultrasound images for real-time hybrid image-based targeting of the biopsy needle. PET/CT with (18)F-FMAU was helpful in localizing the nonstandard biopsy sites that on histopathology revealed suspected tumor deposits.
authors.affiliation: From the Departments of *Radiology and †Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
authors.forename: Hossein
authors.initials: H
authors.lastname: Jadvar
authors.forename: Kai
authors.initials: K
authors.lastname: Chen
authors.forename: Osamu
authors.initials: O
authors.lastname: Ukimura
mesh_terms: D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives; D061765:Endoscopic Ultrasound-Guided Fine Needle Aspiration; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D001086:Arabinofuranosyluracil; C034935:clevudine